Phase I clinical trial of rx108, a new antitumor drug of Suzhou Runxin biology, in Australia

Recently, Suzhou Runxin Biotechnology Co., Ltd (Runxin Biology), an enterprise in Suzhou biological nano Park, announced that it has started the phase I clinical trial of its self-developed class 1.1 small molecule new drug rx108 in Australia Compared with the traditional anti-cancer drugs, it has the anti-tumor characteristics of "one target, multiple points", can target tumor cells, achieve the purpose of high efficiency and low toxicity, and will be used for liver cancer and colon cancer And so on Liver cancer is one of the common malignant tumors in China, but there is no effective treatment At the same time, liver cancer is not sensitive to chemotherapy At present, the remission rate of chemotherapy drugs for liver cancer is less than 20%, and the chemotherapy for liver cancer is limited due to serious adverse reactions Currently widely used in the clinical treatment of advanced liver cancer drugs, from the efficacy point of view is only to extend the total survival period of patients with advanced liver cancer, but the symptoms have not been improved, while the incidence of adverse reactions is high Rx108 is a new Na + / K + - ATPase inhibitor By inhibiting Na + / K + - ATPase, it can cause several signal pathways to cross play a role, leading to tumor cell cycle arrest, autophagy and apoptosis Therefore, rx108 can play an anti-tumor role in a variety of ways, with the anti-tumor characteristics of "one target, multiple points" In vivo pharmacodynamics study showed that rx108 showed significant antitumor effect in human hepatoma, colon cancer and other nude mice transplanted tumor models The signal transduction function of Na + / K + - ATPase plays an important role in the process of tumor occurrence, development, cell proliferation and apoptosis According to the introduction of R & D personnel of Runxin biology, there are differences in the activity and expression of Na + / K + - ATPase in tumor cells and normal cells, which makes rx108, like a targeted missile, able to target tumor cells and achieve the purpose of high efficiency and low toxicity "If rx108 is successfully developed, it will become the first anti-tumor small molecule drug with a new mechanism of action in the world, which is bound to promote the development of anti-tumor treatment and bring good news to cancer patients, with great clinical significance and economic and social benefits At present, if the phase I clinical trial starts smoothly in Australia, it can be completed in 3-4 years In China, rx108 is expected to start clinical trials by the end of this year " Said Dr Qian Xiangping, President and CEO of Runxin biology "Na + / K + - ATPase is a unique and novel anti-tumor target," said Dr Paul de Souza, professor and chairman of medical oncology, School of medicine, University of Western Sydney We hope that rx108 can have good curative effect in many kinds of cancers, so as to become a new anti-tumor drug " It is understood that Suzhou Runxin Biotechnology Co., Ltd is located in Suzhou Biological Nanotechnology park It is a high-tech company specializing in the research and development of innovative drugs It was founded by a returned technology team with many years of rich experience in the field of biomedicine Based on the self-developed targeted drug discovery platform, the company has successfully developed a number of small molecule candidate drugs and lead compounds series with independent intellectual property rights, aiming at the development of innovative drugs in two major fields of tumor and neurodegenerative diseases At present, its biological nano park has gathered more than 400 innovative biomedical enterprises, and has the most complete biomedical industry chain in the field of new drug research and development in China Many enterprises, such as Borui, Paige and Kaifa, have obtained class 1.1 clinical certificate for new drugs.